UNASSIGNED: evaluate the signifcance of cyclo-oxygenase-2 (COX-2) expression in SP.
UNASSIGNED: Immunohistochemistry for COX-2 was performed on SP samples and middle turbinates from chronic rhinosinusitis without nasal polyps controls obtained during surgical resection between 2009-2017. A positive stain was defined as having 10% or more cells exhibiting diffuse immunoreactivity. Comparisons were performed using Fisher Exact tests, t-tests, and ANOVA.
UNASSIGNED: The study included 67 tumor samples and 9 controls from two academic institutions. The mean age of the SP group was 55.4 years and 53.2 years in the control group (p = 0.71). Thirty-nine (58.2%) SP patients had previous surgery compared to 1 (11.1%) in the control group (p = 0.01). The most common tumor attachment sites were the maxillary (47.8%) and ethmoid (25.4%) sinuses. Fifteen (22.4%) SP samples stained strongly positive for COX-2 and 24 (35.8%) stained weakly positive compared to no positive stains in the control group (p < 0.01). When stratified by COX-2 intensity, there were no statistically significant differences in gender, smoking history, history of previous sinus surgery, site of attachment, papilloma subtype, or future recurrence between SP samples.
UNASSIGNED: COX-2 was overexpressed in 58.2% of SP cases, and strongly positive in 22.4% of cases, compared to no positive staining among controls. No significant differences in COX-2 expression were observed between SP subtypes or recurrent tumors. Further studies are warranted to evaluate COX-2 as a possible therapeutic target in tumors that overexpress the enzyme.
■评估环加氧酶-2(COX-2)在SP中表达的意义。
■对2009-2017年手术切除期间获得的无鼻息肉的慢性鼻-鼻窦炎的SP样本和中鼻甲进行了COX-2的免疫组织化学。阳性染色被定义为具有10%或更多的表现出弥漫性免疫反应性的细胞。使用Fisher精确检验进行比较,t检验,和ANOVA。
■该研究包括来自两个学术机构的67个肿瘤样本和9个对照。SP组的平均年龄为55.4岁,对照组为53.2岁(p=0.71)。39例(58.2%)SP患者曾接受过手术,而对照组为1例(11.1%)(p=0.01)。最常见的肿瘤附着部位是上颌窦(47.8%)和筛窦(25.4%)。与对照组中无阳性染色相比,15个(22.4%)SP样品对COX-2染色为强阳性,24个(35.8%)SP样品染色为弱阳性(p<0.01)。当通过COX-2强度分层时,性别差异无统计学意义,吸烟史,既往鼻窦手术史,附件的位置,乳头状瘤亚型,或SP样本之间的未来复发。
■COX-2在58.2%的SP病例中过度表达,在22.4%的病例中强阳性,与对照组中无阳性染色相比。在SP亚型或复发性肿瘤之间未观察到COX-2表达的显着差异。需要进一步的研究来评估COX-2作为过表达该酶的肿瘤中可能的治疗靶标。